A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors (NCT06952010)
A Phase 1 Dose Escalation and Expansion Study of XB628 as a Single Agent and in Combination With Zanzalintinib in Participants With Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
Who can join: Review the eligibility criteria below.
Location: Exelixis Clinical Site #5 — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Exelixis Clinical Site #5 — San Francisco, California
- Exelixis Clinical Site #4 — New Haven, Connecticut
- Exelixis Clinical Site #8 — Tampa, Florida
- Exelixis Clinical Site #10 — Boston, Massachusetts
- Exelixis Clinical Site #11 — Boston, Massachusetts
- Exelixis Clinical Site #6 — St Louis, Missouri
- Exelixis Clinical Site #7 — New York, New York
- Exelixis Clinical Site #1 — Hickory, North Carolina
- Exelixis Clinical Site #3 — Nashville, Tennessee
- Exelixis Clinical Site #9 — Houston, Texas
- Exelixis Clinical Site #2 — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: 1-888-EXELIXIS (888-393-5494)
Email: druginfo@exelixis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.